Holen Sie sich die Stockscreener-App
61.73
1.01%
0.62
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
BioMarin Pharmaceutical EVP Trades $381K In Company Stock - Benzinga
DNB Asset Management AS Acquires 154,954 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About BioMarin Pharm - GuruFocus
Friberg, Biomarin Pharmaceutical EVP, sells $381k in stock By Investing.com - Investing.com Australia
Insider Selling: BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Sells 6,326 Shares of Stock - MarketBeat
Davis, Biomarin Pharmaceutical EVP sells $1.6m in shares - Investing.com
BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo - Yahoo Finance
BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Primecap Management Co. CA - MarketBeat
H.C. Wainwright cuts BioMarin stock price target on competition By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2025 Earnings Call Transcript - Insider Monkey
BioMarin Reports Mixed Q4 Results with Earnings Miss - Intellectia AI
Sanford C. Bernstein Increases BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $94.00 - MarketBeat
Guggenheim Issues Pessimistic Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
Bernstein raises BioMarin stock price target on valuation outlook - Investing.com India
Bernstein raises BioMarin stock price target on valuation outlook By Investing.com - Investing.com South Africa
Is BioMarin Pharmaceutical (BMRN) Pricing Match Recent Share Rebound And DCF Upside Potential - Yahoo Finance
HC Wainwright Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $55.00 - MarketBeat
H.C. Wainwright cuts BioMarin stock price target on competition - Investing.com India
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $95.00 at Oppenheimer - Defense World
BioMarin shuts down one-and-done hemophilia gene therapy after failing to sell itSan Francisco Business Times - The Business Journals
BioMarin Leans Into BD As Voxzogo Competition Intensifies - Citeline News & Insights
BioMarin Pharmaceutical Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
BioMarin pulls hemophilia gene therapy Roctavian, taking $240M hit after divestiture efforts flounder - Fierce Pharma
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market - TradingView
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Bitget
BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $95.00 Price Target at Oppenheimer - MarketBeat
BioMarin to Participate in Four Upcoming Investor Conferences in March - PR Newswire
BioMarin Pharmaceutical Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Stifel raises BioMarin stock price target to $68 on Fold deal value - Investing.com India
Earnings call transcript: BioMarin misses Q4 2025 EPS forecast, stock dips - Investing.com Nigeria
Earnings call transcript: BioMarin misses Q4 2025 EPS forecast, stock dips By Investing.com - Investing.com South Africa
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
BioMarin Pharmaceutical Q4 Earnings Call Highlights - Yahoo Finance
BioMarin: Q4 Earnings Snapshot - kare11.com
BMRN: 2025 revenue grew 13% with strong profitability; 2026 set for further growth and pipeline advances - TradingView
BioMarin Pharmaceutical's (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates - Finviz
BioMarin Pharmaceutical (NASDAQ:BMRN) Announces Earnings Results, Misses Estimates By $1.04 EPS - MarketBeat
BioMarin Pharmaceutical Posts Q4 Loss - Nasdaq
BioMarin posts mixed Q4 results, shares edge lower By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Q4 Non-GAAP Earnings Fall, Revenue Rises; 2026 Guidance Issued - marketscreener.com
BioMarin posts mixed Q4 results, shares edge lower - Investing.com
BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: A 38.69% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues - Finviz
BioMarin earnings loom with estimates falling on Voxzogo worries By Investing.com - Investing.com South Africa
BioMarin earnings loom with estimates falling on Voxzogo worries - Investing.com India
(BMRN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Skandinaviska Enskilda Banken AB publ Has $2.34 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Vanguard Group Inc. - MarketBeat
BioMarin Pharmaceutical Earnings: What To Look For From BMRN - Yahoo Finance
Will BioMarin Pharmaceutical Inc. (BM8) stock maintain strong growthRisk Management & Community Consensus Trade Alerts - mfd.ru
BioMarin Pharmaceutical Inc expected to post earnings of 62 cents a shareEarnings Preview - TradingView
A Peek at Biomarin Pharmaceutical's Future Earnings - Benzinga
Countdown to BioMarin (BMRN) Q4 Earnings: Wall Street Forecasts for Key Metrics - Yahoo Finance
Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight - The Malaysian Reserve
BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET - marketscreener.com
1.18%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):